Development of target-specific treatments in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Development of target-specific treatments in multiple myeloma.

Development of target-specific treatments in multiple myeloma.

http://www.wikidata.org/entity/Q37771370

about

Arsenic exposure and cancer mortality in a US-based prospective cohort: the strong heart study Emerging strategies and therapies for treatment of Paget's disease of bone.High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.The evolving use of arsenic in pharmacotherapy of malignant disease.Emerging antibodies for the treatment of multiple myeloma.The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib.Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma.

P2860

Q28391899-41038A48-E533-476B-B4EC-24B6BB8F9AA1 Q34987305-C1EA8BF7-2D24-498A-BE38-B2A18273F165 Q35194860-4E03723A-149B-4E56-867F-105D339DD4B4 Q38089629-4EF76F72-70F0-4214-A19F-82A0EFC7B8D2 Q38838239-FB284093-C3A9-4BDE-92CE-F15820B616C2 Q39210830-D567FACF-3A86-4C96-93F8-10F574C1D1E4 Q42098281-462D7C24-055E-4B71-8C1F-D4B09A5604F4 Q42138375-57342362-D004-4E38-BD68-C0161505E91C Q49601769-10F3B154-0C19-4EE9-BA71-9777F30BFDD3

P2860

Development of target-specific treatments in multiple myeloma.

http://www.wikidata.org/entity/Q37771370

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 July 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development of target-specific treatments in multiple myeloma.

@en

Development of target-specific treatments in multiple myeloma.

@nl

type

label

Development of target-specific treatments in multiple myeloma.

@en

Development of target-specific treatments in multiple myeloma.

@nl

prefLabel

Development of target-specific treatments in multiple myeloma.

@en

Development of target-specific treatments in multiple myeloma.

@nl

P1433

Q37771370-01FCE1F7-1C14-4837-A91C-04483370A0E8

P1476

Q37771370-E90CDC13-D67D-49ED-B179-6C9180EE55EB

P2093

Q37771370-32CF56DC-8613-45DC-99C5-48201C317254

Q37771370-AFCE1E40-E10C-4EB9-9B9E-80E16FD54295

Q37771370-F3D7E098-DCC4-4AD0-8AF5-C776C296ACB9

Q37771370-F4E2F6E5-9DF2-4EC0-982C-3FDC03C2F922

P2860

Q37771370-07B0BF25-8EDF-4541-8305-24CC87E05580

Q37771370-0CEFB066-B673-40FA-B351-9F3766821D7E

Q37771370-0DECBECA-ECEF-4893-A8B3-AA4A7096D6BA

Q37771370-10FE8303-656E-4389-96A7-D6039E1FE7DF

Q37771370-1390E303-7C7D-42E8-BE5D-203C97E23DF5

Q37771370-141B36BC-02B1-4A9D-9841-287D62483BE9

Q37771370-18DCFBA0-0EF6-4CF9-81E5-FE666C7078E5

Q37771370-1F3EED1F-B410-4092-B3DF-66913CDEC114

Q37771370-20A363A7-92EA-4FB6-8440-9FB5A0212EE6

Q37771370-20B5BAAF-F89B-4EAA-9C03-74C2C84F6A32

P304

Q37771370-BD4350D9-D5E7-4557-9363-8BE173D34E6E

P31

Q37771370-856DE8CD-C414-4FFC-A70B-0FDC6D2B2211

P356

Q37771370-F1967FA4-C981-41B9-8A64-86D1B064F443

P407

Q37771370-4FD0B45D-D8E5-4F0D-9EDC-38DEDD4A5D54

P433

Q37771370-36574D03-9B4A-4C7D-BB5D-882690BF4B5F

P478

Q37771370-2623A294-67CD-48F8-A754-5EDCEE5B77B5

P577

Q37771370-B3F4FE5C-CF3F-4A5D-9687-71BC237414BA

P5875

Q37771370-69389813-E117-4DA2-A2AC-8CEA643F0CBE

P698

Q37771370-52C62BAA-B7D2-4E06-897B-3D4CE361111D

P932

Q37771370-3017A9B8-82AD-4D1E-B07B-BECB14466654

P356

J.1365-2141.2010.08262.X

P1433

British Journal of Haematology

P1476

Development of target-specific treatments in multiple myeloma.

@en

P2093

Asher A Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

Donna E Reece

http://www.w3.org/2001/XMLSchema#string

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

Kelvin P Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

Targeting survivin in cancer therapy

HSP90 and the chaperoning of cancer

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

P304

3-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2010.08262.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

151

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45147486

http://www.w3.org/2001/XMLSchema#string

P698

20618339

http://www.w3.org/2001/XMLSchema#string

P932

3698607

http://www.w3.org/2001/XMLSchema#string